AstraZeneca Stock Surges on Upbeat Earnings, Forecast

Options volume is running at four times the intraday average

Deputy Editor
Nov 10, 2022 at 11:25 AM
facebook twitter linkedin

AstraZeneca PLC (NASDAQ:AZN) stock is up 7% at $65.30 at last glance, after the biotech name posted an upbeat third-quarter report and raised forecast. The company posted earnings of 84 cents per share on revenue of $10.98 billion, beating analyst estimates of 72 cents per share on $10.91 billion, and lifted its full-year guidance due to strong demand for its cancer drugs.

Today's pop has AZN gapping above pressure at its 100-day moving average as well as the $62 level. A short-term dip could be overdue, however, per the stock's 14-day relative strength index (RSI) of 87.3, which sits firmly in "overbought" territory. Year-to-date, the equity is currently up 11.9%. 

Analysts have yet to chime in after the event, but the majority already lean bullish. Of the seven in coverage, five carry a "strong buy" rating on AstraZeneca stock. Plus, the 12-month consensus price target of $71.90 is a 10.1% premium to current levels. 

Options volume is running at four times the intraday average, with 3,513 calls and 1,699 puts across the tape so far. The weekly 11/11 62-strike call is the most popular, followed by the December 62.50 call, with new positions being opened at the latter. 


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners